108 related articles for article (PubMed ID: 23438071)
1. The JR blood group system: identification of alleles that alter expression.
Hue-Roye K; Zelinski T; Cobaugh A; Lomas-Francis C; Miyazaki T; Tani Y; Westhoff CM; Reid ME
Transfusion; 2013 Nov; 53(11):2710-4. PubMed ID: 23438071
[TBL] [Abstract][Full Text] [Related]
2. A new ABCG2 null allele with a 27-kb deletion including the promoter region causing the Jr(a-) phenotype.
Ogasawara K; Osabe T; Suzuki Y; Tsuneyama H; Isa K; Kawai M; Obara K; Ogiyama Y; Ito S; Uchikawa M; Satake M; Tadokoro K
Transfusion; 2015 Jun; 55(6 Pt 2):1467-71. PubMed ID: 25522810
[TBL] [Abstract][Full Text] [Related]
3. The JR blood group system (ISBT 032): molecular characterization of three new null alleles.
Hue-Roye K; Lomas-Francis C; Coghlan G; Zelinski T; Reid ME
Transfusion; 2013 Jul; 53(7):1575-9. PubMed ID: 23066723
[TBL] [Abstract][Full Text] [Related]
4. Defining the Jr(a-) phenotype in the Japanese population.
Tanaka M; Kamada I; Takahashi J; Kimura K; Matsukura H; Tani Y
Transfusion; 2014 Feb; 54(2):412-7. PubMed ID: 23713577
[TBL] [Abstract][Full Text] [Related]
5. Molecular analysis of immunized Jr(a-) or Lan- patients and validation of a high-throughput genotyping assay to screen blood donors for Jr(a-) and Lan- phenotypes.
Haer-Wigman L; Ait Soussan A; Ligthart P; de Haas M; van der Schoot CE
Transfusion; 2014 Jul; 54(7):1836-46. PubMed ID: 24456066
[TBL] [Abstract][Full Text] [Related]
6. A review of the JR blood group system.
Castilho L; Reid ME
Immunohematology; 2013; 29(2):63-8. PubMed ID: 24094238
[TBL] [Abstract][Full Text] [Related]
7. ABCG2 null alleles define the Jr(a-) blood group phenotype.
Zelinski T; Coghlan G; Liu XQ; Reid ME
Nat Genet; 2012 Jan; 44(2):131-2. PubMed ID: 22246507
[TBL] [Abstract][Full Text] [Related]
8. Expression levels of ABCG2 on cord red blood cells and study of fetal anemia associated with anti-Jr(a).
Fujita S; Kashiwagi H; Tomimatsu T; Ito S; Mimura K; Kanagawa T; Endo M; Miyoshi T; Okamura Y; Tani Y; Tomiyama Y; Kimura T
Transfusion; 2016 May; 56(5):1171-81. PubMed ID: 26868047
[TBL] [Abstract][Full Text] [Related]
9. Two novel ABCG2 alleles resulting in a Jr(a-) phenotype.
Berardi P; Cote J; Vege S; Aeschlimann J; Cserti-Gazdewich C; Westhoff CM
Transfusion; 2017 Nov; 57(11):2811-2812. PubMed ID: 28836283
[No Abstract] [Full Text] [Related]
10. Null alleles of ABCG2 encoding the breast cancer resistance protein define the new blood group system Junior.
Saison C; Helias V; Ballif BA; Peyrard T; Puy H; Miyazaki T; Perrot S; Vayssier-Taussat M; Waldner M; Le Pennec PY; Cartron JP; Arnaud L
Nat Genet; 2012 Jan; 44(2):174-7. PubMed ID: 22246505
[TBL] [Abstract][Full Text] [Related]
11. Impact of functional ABCG2 polymorphisms on the adverse effects of gefitinib in Japanese patients with non-small-cell lung cancer.
Akasaka K; Kaburagi T; Yasuda S; Ohmori K; Abe K; Sagara H; Ueda Y; Nagao K; Imura J; Imai Y
Cancer Chemother Pharmacol; 2010 Sep; 66(4):691-8. PubMed ID: 20035425
[TBL] [Abstract][Full Text] [Related]
12. A new genetic background for the Jr(a-) blood group phenotype caused by the ABCG2*439T allele encoding a p.Arg147Trp change.
Wieckhusen C; Rink G; Scharberg EA; Rothenberger S; Stürtzel A; Richter E; Bugert P
Transfusion; 2017 Dec; 57(12):3063-3064. PubMed ID: 29106709
[No Abstract] [Full Text] [Related]
13. Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin.
Keskitalo JE; Pasanen MK; Neuvonen PJ; Niemi M
Pharmacogenomics; 2009 Oct; 10(10):1617-24. PubMed ID: 19842935
[TBL] [Abstract][Full Text] [Related]
14. An update on the JR blood group system.
Castilho L
Immunohematology; 2019 Jun; 35(2):43-44. PubMed ID: 31246485
[TBL] [Abstract][Full Text] [Related]
15. Genotyping of the ABCG2 gene using Matrix-Associated Laser Desorption/Ionisation, Time-of-Flight Mass Spectrometry.
Tanaka M; Kamada I; Takahashi J; Kimura T; Tani Y
Transfus Med; 2018 Jun; 28(3):255-260. PubMed ID: 28940904
[TBL] [Abstract][Full Text] [Related]
16. Alleles of the LAN blood group system: molecular and serologic investigations.
Reid ME; Hue-Roye K; Huang A; Velliquette RW; Tani Y; Westhoff CM; Lomas-Francis C; Zelinski T
Transfusion; 2014 Feb; 54(2):398-404. PubMed ID: 23763549
[TBL] [Abstract][Full Text] [Related]
17. Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype.
Sparreboom A; Gelderblom H; Marsh S; Ahluwalia R; Obach R; Principe P; Twelves C; Verweij J; McLeod HL
Clin Pharmacol Ther; 2004 Jul; 76(1):38-44. PubMed ID: 15229462
[TBL] [Abstract][Full Text] [Related]
18. ATP-binding cassette transporter ABCG2 (BCRP) and ABCB1 (MDR1) variants are not associated with disease susceptibility, disease phenotype response to medical therapy or need for surgeryin Hungarian patients with inflammatory bowel diseases.
Fischer S; Lakatos PL; ; Lakatos L; Kovacs A; Molnar T; Altorjay I; Papp M; Szilvasi A; Tulassay Z; Osztovits J; Papp J; Demeter P; Schwab R; Tordai A; Andrikovics H
Scand J Gastroenterol; 2007 Jun; 42(6):726-33. PubMed ID: 17505995
[TBL] [Abstract][Full Text] [Related]
19. Role of UGT1A1*6, UGT1A1*28 and ABCG2 c.421C>A polymorphisms in irinotecan-induced neutropenia in Asian cancer patients.
Jada SR; Lim R; Wong CI; Shu X; Lee SC; Zhou Q; Goh BC; Chowbay B
Cancer Sci; 2007 Sep; 98(9):1461-7. PubMed ID: 17627617
[TBL] [Abstract][Full Text] [Related]
20. SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers.
Ieiri I; Suwannakul S; Maeda K; Uchimaru H; Hashimoto K; Kimura M; Fujino H; Hirano M; Kusuhara H; Irie S; Higuchi S; Sugiyama Y
Clin Pharmacol Ther; 2007 Nov; 82(5):541-7. PubMed ID: 17460607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
